Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Michael Acurio

Orthopaedic Surgery of the Spine Bossier City, LA Medical Doctor

NPI 1982606356 CMS profile 561691

2005 Landry Drive, Bossier City, LA 71111

Open in the dashboard

General payments

$6,097

219 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Michael Acurio of Bossier City, LA is reported in the CMS Open Payments database as having received $6,097 across 219 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 37th percentile of Orthopaedic Surgery of the Spine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $571 10
2024 General $787 30
2023 General $989 34
2022 General $890 43
2021 General $423 16
2020 General $1,696 48
2019 General $743 38

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Michael Acurio
  • Orthopaedic Surgery of the Spine median
  • Middle half of Orthopaedic Surgery of the Spine
  • National median

In program year 2025, general payments to Michael Acurio were reported at $571. Among 1,704 Orthopaedic Surgery of the Spine profiles paid that year, the median was $2,061 and the middle half received between $347 and $14,651.

Show as a table
Year Michael Acurio Orthopaedic Surgery of the Spine median Middle half National median
2019 $743 $2,106 $337–$18,608 $163
2020 $1,696 $1,213 $156–$15,082 $114
2021 $423 $1,834 $271–$15,617 $132
2022 $890 $2,015 $320–$17,036 $149
2023 $989 $1,925 $336–$14,599 $160
2024 $787 $2,110 $341–$12,483 $164
2025 $571 $2,061 $347–$14,651 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Stryker Corporation $2,888 82 payments
  2. Smith+Nephew, Inc. $1,635 50 payments
  3. Horizon Therapeutics plc $456 30 payments
  4. AbbVie, Inc. $172 8 payments
  5. KCI USA, Inc $122 9 payments
  6. Boston Scientific Corporation $116 4 payments
  7. Dynasplint Systems Inc. $97 6 payments
  8. Flexion Therapeutics, Inc. $66 3 payments
  9. Sanara MedTech Inc. $64 1 payment
  10. Innovation Technologies Inc $63 2 payments
  11. Other $419 24 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $5,388 215 payments
  2. Travel and Lodging $709 4 payments
Products named General payments · program years 2019–2025
  1. MAKO Knees, Hips $1,684 65 payments
  2. MAKO Knees, Hips $1,063 14 payments
  3. N/A $311 5 payments
  4. DUEXIS $272 24 payments
  5. NA $215 3 payments
  6. DALVANCE $172 8 payments
  7. REGENETEN Shoulder $165 7 payments
  8. SPATIAL FRAME $157 5 payments
  9. Bioinductive Implant with Arthroscopic Delivery System - Medium $157 2 payments
  10. Regeneten $153 5 payments
  11. Other $2,110 87 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 34 drugs

Part D claims

4,227

Median for Orthopedic Surgery: 203

Drug cost

$57,127

Median for Orthopedic Surgery: $1,433

Branded share of claims

33.1%

Median for Orthopedic Surgery: 11.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Xarelto Rivaroxaban Brand 72 $15,892
Hydrocodone-Acetaminophen Hydrocodone/Acetaminophen Brand 844 $9,856
Celecoxib Generic 297 $6,151
Oxycodone-Acetaminophen Oxycodone Hcl/Acetaminophen Brand 430 $6,016
Gabapentin Generic 141 $4,479
Prednisone Generic 780 $3,191
Methylprednisolone Generic 340 $2,015
Hydroxyzine Hcl Generic 208 $1,602
Tramadol Hcl Generic 202 $1,502
Duloxetine Hcl Generic 97 $1,044

The 10 drugs with the highest cost, of 34 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 18,934 Part D prescribers listed as Orthopedic Surgery; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 112 billing codes

Paid by Medicare

$438,789

Of which drugs: $66,924

Medicare patients

1,002

Average age 74

Services billed

10,786

638 women, 364 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 75%
Diabetes 34%
Ischemic heart disease 29%
Chronic kidney disease 20%
Depression 19%
Atrial fibrillation 16%
Osteoporosis 15%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, triamcinolone acetonide, preservative-free, extended-release, microsphere formulation, 1 mg J3304 Office 22 1,984 $26,855
Hyaluronan or derivative, euflexxa, for intra-articular injection, per dose J7323 Office 69 233 $21,295
Hyaluronan or derivative, synvisc or synvisc-one, for intra-articular injection, 1 mg J7325 Office 21 1,584 $10,994
Injection, betamethasone acetate 3 mg and betamethasone sodium phosphate 3 mg J0702 Office 267 945 $4,899
Injection, triamcinolone acetonide, not otherwise specified, 10 mg J3301 Office 67 476 $336

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

2 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
DALVANCE
  • AbbVie, Inc. $40
$40 — —
TEFLARO
  • AbbVie, Inc. $9
$9 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

Records

219 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Orthopaedic Surgery of the Spine in Louisiana

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record